W. Dalton Dietrich
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, W. Dalton Dietrich sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
W. Dalton Dietrich: 4 sponsored US clinical trials, 1 recruiting.
W. Dalton Dietrich sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral Nerve Injury, with 1 trials.
Upper-quartile sponsor footprint
W. Dalton Dietrich sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)
NCT05541250
Autologous Human Schwann Cells in Peripheral Nerve Repair
NCT03999424
The Safety of ahSC in Chronic SCI With Rehabilitation
NCT02354625
Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI
NCT01739023
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Therapeutic Areas
What is open in the W. Dalton Dietrich pipeline
1 recruiting of 4 indexed (25% open); 3 completed (75%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Peripheral Nerve Injury (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
W. Dalton Dietrich: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
W. Dalton Dietrich sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this W. Dalton Dietrich page
4 registered trials is a research-attention snapshot, not an endorsement of W. Dalton Dietrich or any single study.
- 1 of W. Dalton Dietrich's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Peripheral Nerve Injury is the condition W. Dalton Dietrich studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral Nerve Injury trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
W. Dalton Dietrich pipeline card: 4 registered trials from official public datasets.Report a data error.